1-2 of 2
David Hakimian
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Results of a Phase II Study of Bortezomib in Patients with Relapsed or Refractory Indolent Lymphoma.

Nicholas Di Bella, MD, Raymond Taetle, MD, Kathryn S. Kolibaba, MD, Thomas E Boyd, MD, Robert N Raju, MD, David N Barrera, DO, Ernest Cochran, MD, Philip Dien, MD, David Hakimian, MD, Roger M. Lyons, MD, Peter J Schlegel, MD, Svetislava J Vukelja, MD, Julie Boston, RN, Kristi A Boehm, MS, Yunfei Wang, MS, Lina Asmar, PhD
Journal: Blood
Blood (2008) 112 (11): 1572.
https://doi.org/10.1182/blood.V112.11.1572.1572
Published: 2008
Journal Articles

Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience

Clinical Trials & Observations
Punit Chadha, Alfred W. Rademaker, Prateek Mendiratta, Benjamin Kim, Darren M. Evanchuk, David Hakimian, LoAnn C. Peterson, Martin S. Tallman
Journal: Blood
Blood (2005) 106 (1): 241–246.
https://doi.org/10.1182/blood-2005-01-0173
Published: 2005